BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Eylea (Aflibercept) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Eylea (Aflibercept)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04932980-7584@assetmemo.bio
DTSTAMP:20261121T005651Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Eylea (Aflibercept): Phase na readout est. (NCT04932980)
DESCRIPTION:Eylea (Aflibercept)\, phase na\, Age-Related Macular Degenerati
 on.\nStudy: Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD\n
 Estimated primary completion: June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/aflibercept#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04932980
URL:https://assetmemo.bio/drug/aflibercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02645266-7584@assetmemo.bio
DTSTAMP:20261121T005651Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Eylea (Aflibercept): Phase na readout est. (NCT02645266)
DESCRIPTION:Eylea (Aflibercept)\, phase na\, Diabetic Macular Edema.\nStudy
 : Mean Visual Acuity Changes Following Five Injections of Aflibercept\nEst
 imated primary completion: September 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/aflibercept#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT02645266
URL:https://assetmemo.bio/drug/aflibercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07438119-7584@assetmemo.bio
DTSTAMP:20261121T005651Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Eylea (Aflibercept): Phase 4 readout est. (NCT07438119)
DESCRIPTION:Eylea (Aflibercept)\, phase 4\, Diabetic Macular Edema.\nStudy:
  Efficacy Comparison of DExamethasone Intravitreal Implant Combined With A
 flibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory
  Diabetic Macular Edema Patients\nEstimated primary completion: 15 Septemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/aflibercept#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0743
 8119
URL:https://assetmemo.bio/drug/aflibercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365371-7584@assetmemo.bio
DTSTAMP:20261121T005651Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Eylea (Aflibercept): Phase 4 readout est. (NCT07365371)
DESCRIPTION:Eylea (Aflibercept)\, phase 4\, Age-Related Macular Degeneratio
 n.\nStudy: A Prospective\, Multicenter\, Open-label\, Randomized Clinical 
 Trial to Evaluate the Efficacy\, Durability\, and Safety of Aflibercept 8m
 g in Different Treatment Regimens in Chinese Patients With Polypoidal Chor
 oidal Vasculopathy (PCV)\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/aflibercept#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07365371
URL:https://assetmemo.bio/drug/aflibercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07891182-7584@assetmemo.bio
DTSTAMP:20261121T005651Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Eylea (Aflibercept): Phase 2 readout est. (NCT07891182)
DESCRIPTION:Eylea (Aflibercept)\, phase 2.\nStudy: VGFTe-(HD)-OD-2566: Adju
 nctive Aflibercept Ahmed Glaucoma Valve (AAA) Study\nEstimated primary com
 pletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 flibercept#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07891182
URL:https://assetmemo.bio/drug/aflibercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07612904-7584@assetmemo.bio
DTSTAMP:20261121T005651Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Eylea (Aflibercept): Phase 4 readout est. (NCT07612904)
DESCRIPTION:Eylea (Aflibercept)\, phase 4\, Diabetic Macular Edema.\nStudy:
  Zhuochuming®-3T&E-DME Study (Treatment-naïve Patients)\nEstimated prima
 ry completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/aflibercept#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07612904
URL:https://assetmemo.bio/drug/aflibercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07940998-7584@assetmemo.bio
DTSTAMP:20261121T005651Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Eylea (Aflibercept): Phase 4 readout est. (NCT07940998)
DESCRIPTION:Eylea (Aflibercept)\, phase 4\, Age-Related Macular Degeneratio
 n.\nStudy: Observation on the Efficacy of Aflibercept 8mg Intravitreal Inj
 ection Solution on Retinal Fluid in nAMD Patients With PED\nEstimated prim
 ary completion: 30 September 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/aflibercept#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07940998
URL:https://assetmemo.bio/drug/aflibercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
